Dulaglutide — GLP-1 receptor agonist. Study the mechanism, listed uses and warnings from the US label on one sourced card.
Generic name
Dulaglutide
Brands
Trulicity
Class
GLP-1 receptor agonist
Mechanism
Activates GLP-1 receptors on beta cells, raising cAMP for glucose-dependent insulin release; lowers glucagon, slows gastric emptying.
Used for
Adjunct to diet and exercise for glycemic control in adults and children aged 10 years and older with type 2 diabetes; Reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors
Thyroid C-cell tumors occurred in rats; whether the medicine causes these tumors in humans is unknown. It is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.
Warnings
Acute pancreatitis; Hypoglycemia with insulin or secretagogues; Severe GI reactions / acute kidney injury
Label date: 20260616 · For learning, not clinical decisions. US label and brand information; always consult the current source.
Source snapshot checked: 2026-10-21. The source document and selected fields were compared. The complete card has not had an independent clinical review.
Mechanism: GLP-1 analogue that selectively binds and activates the GLP-1 receptor; albumin binding gives it a long half-life.
On both cards: Common side effects — Nausea; Diarrhea; Vomiting; Abdominal pain · Warnings — Acute pancreatitis; Hypoglycemia with insulin or secretagogues · Interactions — Oral medications (delayed gastric emptying)
Only on the Semaglutide card: Used for — As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes; Reduction of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; Reduction of sustained eGFR decline, end-stage kidney disease or cardiovascular death in adults with type 2 diabetes and chronic kidney disease · Common side effects — Constipation · Warnings — Diabetic retinopathy complications · Interactions — Insulin secretagogues (e.g. sulfonylureas); Insulin
Mechanism: Activates both GIP and GLP-1 receptors; GLP-1 regulates appetite and caloric intake. A fatty diacid prolongs half-life.
On both cards: Common side effects — Nausea; Diarrhea; Vomiting; Abdominal pain · Warnings — Acute pancreatitis · Interactions — Oral medications (delayed gastric emptying)
Only on the Tirzepatide card: Used for — With reduced-calorie diet and increased physical activity, long-term weight reduction/maintenance in adults with obesity or overweight plus at least one weight-related comorbidity; With reduced-calorie diet and increased physical activity, moderate-to-severe obstructive sleep apnea in adults with obesity · Common side effects — Constipation · Warnings — Severe GI adverse reactions; Acute gallbladder disease · Interactions — Insulin or sulfonylureas
Mechanism: Acylated GLP-1 analog; activates the GLP-1 receptor (adenylyl cyclase-coupled) to improve glycemic control.
On both cards: Common side effects — Nausea; Diarrhea; Vomiting; Decreased appetite · Warnings — Acute pancreatitis; Hypoglycemia with insulin or secretagogues
Only on the Liraglutide card: Used for — Adjunct to diet and exercise to improve glycemic control in adults and children aged 10 years and older with type 2 diabetes · Common side effects — Constipation · Warnings — Acute kidney injury from volume depletion · Interactions — Oral drugs (delayed gastric emptying)
An item counts as shared only when both cards use the same wording. If a card does not list an item, that is not a statement that the effect never occurs.
Semaglutide: Thyroid C-cell tumors occurred in rodents; whether this occurs in humans is unknown. The product is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.
Liraglutide: Thyroid C-cell tumors occurred in rats and mice; whether the medicine causes these tumors in humans is unknown. It is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.
Capsera